Daiichi Sankyo (DSNKY) and AstraZeneca’s Enhertu has been approved in the European Union as a monotherapy for the treatment of adult patients with unresectable or metastatic hor ...

WSJ goes inside the Swedish army’s fastest-growing and most grueling brigade as a geopolitical battle intensifies in the Arctic. Photo: Eve Hartley Western allies are trying to hash out a bold ...

Sales of Tesla’s Model Y midsize SUV were down 56 percent in February in Europe, including an 81 percent drop in Germany, where it is built. Tesla’s European sales continued their freefall in ...

It turns out Europe’s favorite American import isn’t fast food or Netflix. It’s missiles, and Europe needs to start making its own. Today, Europe is in no position to do so. As is common in asymmetric ...

Japanese drugmaker Daiichi Sankyo’s (TYO:4568) Datroway (datopotamab deruxtecan) has been launched in the company’s home country for the treatment of adults with hormone receptor (HR) positive, HER2 ...

Investors are making a sharp pivot from the United States to Europe, betting that the era of American exceptionalism has peaked while positioning for a European resurgence, driven largely by ...

The European Union and United Kingdom are putting in place new travel rules that will affect Americans going abroad. Some of those rules have been rolled out in recent months, while others have ...

an associate professor of pharmacology and toxicology at Michigan State University, tells Well+Good. This process can just happen naturally after a product is made. In this case, benzene may have ...

In these six charming destinations for Americans to retire in Europe “retirees can enjoy a high-quality lifestyle for under $1,500 a month,” according to a new report from International Living.

When people with no right to stay remain in the EU, the credibility of our entire migration policy is undermined … and [this] diminishes Europe’s ability to attract and retain talent and skills.” With ...

Daiichi Sankyo is stepping up its interest in RNA therapies, teaming with Nosis Biosciences to design drug candidates capable of reaching targets beyond the liver. The Japanese drugmaker is best ...